Loading
A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Radiation Therapy Oncology Group, completed.
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer is a phase 3 interventional study registered as NCT00003139 by Radiation Therapy Oncology Group, with 249 participants recorded, started 1998-03 and reaching its primary completion in 2001-01. Interventions recorded: pilocarpine hydrochloride, Placebo. Conditions recorded: Head and Neck Cancer, Oral Complications.
Linked to the drug Pilocarpine because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pilocarpine, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), NRG Oncology and the tag pipeline.
Shares Pilocarpine and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/